300485.SZ
赛升药业
SZSE · Healthcare · C 制造业 · CN
CNY 9.05
−8.68%Year over year
Reported trailing growth
- Revenue
- +0.8%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- -73.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -18.0%
- EBITDA
- -41.8%
- EBIT
- -63.5%
- Net income
- -58.6%
- EPS
- -58.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026